The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals
Primary Purpose
Sarcopenia
Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Strength training
Protein supplementation
Sponsored by
About this trial
This is an interventional basic science trial for Sarcopenia focused on measuring Sarcopenia, Frailty, Strength training, Autophagy
Eligibility Criteria
Inclusion Criteria:
- Age > 65
- Frail or pre-frail according to the Fried Frailty Criteria or Short Physical Performance Battery (SPPB) score <6.
- Mini Mental State Examination score > 18
Exclusion Criteria:
- Diseases or injuries contraindicating participation
- Lactose intolerance
- Allergy to milk
- Allergy towards local anesthetics (xylocain)
- Use of anticoagulants that cannot be discontinued prior to the muscle biopsy
Sites / Locations
- Norwegian School of Sport Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Strength training + protein supplement
Protein supplement
Arm Description
Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
Daily protein supplementation for 10 weeks.
Outcomes
Primary Outcome Measures
Single fiber specific force
A measure of muscle quality at the single fiber level. Biopsies obtained from m. Vastus Lateralis
Secondary Outcome Measures
Lean mass
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Fat mass
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Bone mineral density
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Muscle strength of m. quadriceps
Maximal isometric and dynamic muscle strength of m. quadriceps
Muscle size of m. quadriceps
Cross-sectional area of m. quadriceps measured by a Computed Tomography scan
Fat infiltration of m. quadriceps
Fat infiltration of m. quadriceps measured by a Computed Tomography scan
Muscle activation
Voluntary activation level during a maximal isometric knee extension using the interpolated twitch technique
Fractional Breakdown Rate
Measurement of fractional breakdown rate by the use of orally provided Deuterium Oxide, biopsies and blood samples
m. Vastus Lateralis thickness
Measured by ultrasound
Chair stand performance
Time (sec) to stand up from a chair five times
Habitual gait velocity
Time (sec) to walk 6 meters at habitual gait velocity
Maximal gait velocity
Time (sec) to walk 6 meters as fast as possible
Level/cellular location of Microtubule-associated protein 1A/1B-light chain 3 (LC3)
Biopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of p62/Sequestosome-1
Biopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of Lysosome-associated membrane glycoprotein 2 (LAMP2)
Biopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of forkhead box O3 (FOXO3a)
Biopsies from m. Vastus Lateralis analyzed by western blot
Phosphorylation status and total level of ribosomal protein S6 kinase beta-1(P70S6K)
Biopsies from m. Vastus Lateralis analyzed by western blot
Phosphorylation status and total level of eukaryotic elongation factor 2 (eEF-2)
Biopsies from m. Vastus Lateralis analyzed by western blot
Phosphorylation status and total level of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP-1)
Biopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of muscle RING-finger protein-1 (Murf-1)
Biopsies from m. Vastus Lateralis analyzed by western blot
Level/cellular location of ubiquitin (Ub)
Biopsies from m. Vastus Lateralis analyzed by western blot
Blood serum glucose
Fasted
Blood serum insulin
Fasted
Blood plasma Hemoglobin A1c (HbA1c)
Fasted
Blood serum Triglycerides
Fasted
Blood serum High-density lipoproteins (HDL)
Fasted
Blood serum Low-density lipoproteins (LDL)
Fasted
Blood serum C-reactive protein (CRP)
Fasted
forkhead box protein O3 (FOXO3A) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
forkhead box protein O1 (FOXO1) mRNA mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
hepatocyte growth factor (HGF) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
insulin-like growth factor I (IGF1) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
myostatin (MSTN) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
E3 ubiquitin-protein ligase TRIM63 (TRIM63) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
p62/Sequestosome-1 mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
muscle RING-finger protein-1 (Murf-1) protein 1 (4EBP-1) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
Atrogin1 mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
Microtubule-associated protein 1A/1B-light chain 3 (LC3) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
BCL2/adenovirus E1B interacting protein 3 (BNIP3) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
PTEN-induced putative kinase 1 (PINK1) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
TNF receptor associated factor 6 (TRAF6) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
transcription factor EB (Tfeb) mRNA
Biopsies from m. Vastus Lateralis analyzed by western blot
Intramyocellular lipids
Oil-Red-O staining of muscle sections. Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Muscle fiber type distribution
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Muscle fiber cross-sectional area
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Muscle satellite cells
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Myonuclei
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Myonuclei number
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Myonuclei location
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Amount of mitochondria
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Location of mitochondria
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Full Information
NCT ID
NCT03326648
First Posted
May 5, 2017
Last Updated
April 10, 2018
Sponsor
Truls Raastad
Collaborators
University of Padova, University of Copenhagen, Tine
1. Study Identification
Unique Protocol Identification Number
NCT03326648
Brief Title
The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals
Official Title
The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
September 1, 2016 (Actual)
Primary Completion Date
December 20, 2017 (Actual)
Study Completion Date
March 1, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Truls Raastad
Collaborators
University of Padova, University of Copenhagen, Tine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate mechanisms underlying the reduction in muscle quality (the ratio between muscle strength and muscle size) with aging, and to investigate how these factors are affected by strength training and protein supplementation. It is already established that muscle quality defined as the ratio between the strength and the size of a muscle is improved with strength training, even in frail elderly individuals. However, the relative contribution of factors such as activation level, fat infiltration, muscle architecture and single fiber function is unknown. The main focus of this study is to investigate the relationship between muscle quality and muscle protein breakdown, as insufficient degradation of proteins is hypothesized to negatively affect muscle quality.
Detailed Description
Aging is associated with impaired skeletal muscle function. This is evident not only by a reduced capacity to generate force and power at the whole muscle level, but also by a decline in individual muscle fiber contraction velocity and force generation. Combined with muscle atrophy, these changes lead to reduced muscle strength and quality and loss off physical function with age. Clinically, muscle quality may be a better indicator of overall functional capacity than absolute muscle strength. Thus, identifying the mechanisms underlying the age-related loss of muscle quality is of high relevance for the prevention of functional impairment with aging. The explanation for the loss of muscle quality with aging seems to be multifactorial, with alterations in voluntary muscle activation, muscle architecture, fat infiltration and impaired contractile properties of single muscle fibers being likely contributors. Single fiber specific force seems to be related to myosin heavy chain (MHC) content, which is thought to reflect the number of available cross-bridges. The reduction of single fiber specific force with aging may thus be a consequence of reduced synthesis of MHC and/or increased concentration of non-contractile tissue (e.g. intramyocellular lipids).
Some studies in mice also indicate attenuated activity in some of the pathways responsible for degradation of muscle proteins with aging (especially autophagy). As a result, damaged proteins and organelles are not removed as effectively as they should, which could ultimately compromise the muscle's ability to produce force. In addition, reduced efficiency of mitophagy and lipophagy (two specific forms of autophagy), may indirectly affect single fiber specific force, through oxidative damage by reactive oxygen species (ROS) and increased levels of intramyocellular lipids, respectively. Although animal studies indicate attenuated autophagic function, exercise seems to restore the activity in this pathway. Whether this also is the case in humans is unknown. Thus, the purpose of this study is to investigate how the different factors contributing to reduced muscle quality in frail elderly individuals, with emphasis on the relationship between muscle quality and autophagy, may be counteracted by a specific strength training program targeting muscle quality and muscle mass.
In this randomized controlled trial the investigators will aim to recruit frail elderly individuals, as muscle quality is shown to be low in this population. As a consequence, the potential for improved muscle quality is expected to be large. Subjects will be randomized to two groups; one group performing strength training twice a week for 10 weeks in addition to receiving daily protein supplementation. The other group will only receive the protein supplement. Several tests will be performed before and after the intervention period, including a test day where a biopsy is obtained both at rest, and 2.5 hours following strength training + protein supplementation or protein supplementation only. This will provide information about the regulation of muscle protein breakdown in a resting state, following protein intake and following strength training in combination with protein intake. As this will be done both before and after the training period, it will also provide information on how long-term strength training affects the activity in these systems.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcopenia
Keywords
Sarcopenia, Frailty, Strength training, Autophagy
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Subjects and testers will not be blinded. All analyses of muscle samples will be performed blinded.
Allocation
Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Strength training + protein supplement
Arm Type
Experimental
Arm Description
Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
Arm Title
Protein supplement
Arm Type
Experimental
Arm Description
Daily protein supplementation for 10 weeks.
Intervention Type
Other
Intervention Name(s)
Strength training
Other Intervention Name(s)
Resistance training
Intervention Description
Heavy load strength training performed twice a week for 10 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Protein supplementation
Intervention Description
Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
Primary Outcome Measure Information:
Title
Single fiber specific force
Description
A measure of muscle quality at the single fiber level. Biopsies obtained from m. Vastus Lateralis
Time Frame
Change from baseline at 10 weeks
Secondary Outcome Measure Information:
Title
Lean mass
Description
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Time Frame
Change from baseline at 10 weeks
Title
Fat mass
Description
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Time Frame
Change from baseline at 10 weeks
Title
Bone mineral density
Description
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Time Frame
Change from baseline at 10 weeks
Title
Muscle strength of m. quadriceps
Description
Maximal isometric and dynamic muscle strength of m. quadriceps
Time Frame
Change from baseline at 10 weeks
Title
Muscle size of m. quadriceps
Description
Cross-sectional area of m. quadriceps measured by a Computed Tomography scan
Time Frame
Change from baseline at 10 weeks
Title
Fat infiltration of m. quadriceps
Description
Fat infiltration of m. quadriceps measured by a Computed Tomography scan
Time Frame
Change from baseline at 10 weeks
Title
Muscle activation
Description
Voluntary activation level during a maximal isometric knee extension using the interpolated twitch technique
Time Frame
Change from baseline at 10 weeks
Title
Fractional Breakdown Rate
Description
Measurement of fractional breakdown rate by the use of orally provided Deuterium Oxide, biopsies and blood samples
Time Frame
Measured over the last 14 days of the intervention period
Title
m. Vastus Lateralis thickness
Description
Measured by ultrasound
Time Frame
Change from baseline at 10 weeks
Title
Chair stand performance
Description
Time (sec) to stand up from a chair five times
Time Frame
Change from baseline at 10 weeks
Title
Habitual gait velocity
Description
Time (sec) to walk 6 meters at habitual gait velocity
Time Frame
Change from baseline at 10 weeks
Title
Maximal gait velocity
Description
Time (sec) to walk 6 meters as fast as possible
Time Frame
Change from baseline at 10 weeks
Title
Level/cellular location of Microtubule-associated protein 1A/1B-light chain 3 (LC3)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Level/cellular location of p62/Sequestosome-1
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Level/cellular location of Lysosome-associated membrane glycoprotein 2 (LAMP2)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Level/cellular location of forkhead box O3 (FOXO3a)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Phosphorylation status and total level of ribosomal protein S6 kinase beta-1(P70S6K)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Phosphorylation status and total level of eukaryotic elongation factor 2 (eEF-2)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Phosphorylation status and total level of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP-1)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Level/cellular location of muscle RING-finger protein-1 (Murf-1)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Level/cellular location of ubiquitin (Ub)
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Blood serum glucose
Description
Fasted
Time Frame
Change from baseline at 10 weeks
Title
Blood serum insulin
Description
Fasted
Time Frame
Change from baseline at 10 weeks
Title
Blood plasma Hemoglobin A1c (HbA1c)
Description
Fasted
Time Frame
Change from baseline at 10 weeks
Title
Blood serum Triglycerides
Description
Fasted
Time Frame
Change from baseline at 10 weeks
Title
Blood serum High-density lipoproteins (HDL)
Description
Fasted
Time Frame
Change from baseline at 10 weeks
Title
Blood serum Low-density lipoproteins (LDL)
Description
Fasted
Time Frame
Change from baseline at 10 weeks
Title
Blood serum C-reactive protein (CRP)
Description
Fasted
Time Frame
Change from baseline at 10 weeks
Title
forkhead box protein O3 (FOXO3A) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
forkhead box protein O1 (FOXO1) mRNA mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
hepatocyte growth factor (HGF) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
insulin-like growth factor I (IGF1) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
myostatin (MSTN) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
E3 ubiquitin-protein ligase TRIM63 (TRIM63) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
p62/Sequestosome-1 mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
muscle RING-finger protein-1 (Murf-1) protein 1 (4EBP-1) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Atrogin1 mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Microtubule-associated protein 1A/1B-light chain 3 (LC3) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
BCL2/adenovirus E1B interacting protein 3 (BNIP3) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
PTEN-induced putative kinase 1 (PINK1) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
TNF receptor associated factor 6 (TRAF6) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
transcription factor EB (Tfeb) mRNA
Description
Biopsies from m. Vastus Lateralis analyzed by western blot
Time Frame
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Title
Intramyocellular lipids
Description
Oil-Red-O staining of muscle sections. Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time Frame
Change from baseline at 10 weeks
Title
Muscle fiber type distribution
Description
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time Frame
Change from baseline at 10 weeks
Title
Muscle fiber cross-sectional area
Description
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time Frame
Change from baseline at 10 weeks
Title
Muscle satellite cells
Description
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time Frame
Change from baseline at 10 weeks
Title
Myonuclei
Description
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time Frame
Change from baseline at 10 weeks
Title
Myonuclei number
Description
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Time Frame
Change from baseline at 10 weeks
Title
Myonuclei location
Description
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Time Frame
Change from baseline at 10 weeks
Title
Amount of mitochondria
Description
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Time Frame
Change from baseline at 10 weeks
Title
Location of mitochondria
Description
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Time Frame
Change from baseline at 10 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age > 65
Frail or pre-frail according to the Fried Frailty Criteria or Short Physical Performance Battery (SPPB) score <6.
Mini Mental State Examination score > 18
Exclusion Criteria:
Diseases or injuries contraindicating participation
Lactose intolerance
Allergy to milk
Allergy towards local anesthetics (xylocain)
Use of anticoagulants that cannot be discontinued prior to the muscle biopsy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Truls Raastad, Prof.
Organizational Affiliation
Norwegian School of Sport Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Norwegian School of Sport Sciences
City
Oslo
ZIP/Postal Code
0863
Country
Norway
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals
We'll reach out to this number within 24 hrs